CDKN2A and neoplasm: We found CD271 expression particularly in the tumor of p16-positive patients to be widespread and intense with a median of 69.0% CD271+ tumor cells, while CD271 expression in p16 negative patients was much more heterogeneously distributed with expression in a median of 44.6% of tumor cells.